nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—SLC22A6—Hydrochlorothiazide—nephrolithiasis	0.498	1	CbGbCtD
Dabrafenib—SLC22A8—Organic anion transport—SLC22A12—nephrolithiasis	0.0348	0.131	CbGpPWpGaD
Dabrafenib—SLC22A6—Organic anion transport—SLC22A12—nephrolithiasis	0.029	0.11	CbGpPWpGaD
Dabrafenib—SLC22A8—nephron—nephrolithiasis	0.0164	0.123	CbGeAlD
Dabrafenib—SLC22A8—Organic cation/anion/zwitterion transport—SLC22A12—nephrolithiasis	0.0162	0.0611	CbGpPWpGaD
Dabrafenib—SLC22A6—Organic cation/anion/zwitterion transport—SLC22A12—nephrolithiasis	0.0135	0.051	CbGpPWpGaD
Dabrafenib—SLC22A8—urine—nephrolithiasis	0.0131	0.0989	CbGeAlD
Dabrafenib—RAF1—Endothelin Pathways—ADCY10—nephrolithiasis	0.00894	0.0337	CbGpPWpGaD
Dabrafenib—SIK1—nephron tubule—nephrolithiasis	0.00763	0.0575	CbGeAlD
Dabrafenib—SIK1—renal system—nephrolithiasis	0.00694	0.0523	CbGeAlD
Dabrafenib—SIK1—kidney—nephrolithiasis	0.00671	0.0506	CbGeAlD
Dabrafenib—SIK1—cortex of kidney—nephrolithiasis	0.00653	0.0493	CbGeAlD
Dabrafenib—CYP3A4—urine—nephrolithiasis	0.00651	0.049	CbGeAlD
Dabrafenib—RAF1—nephron tubule—nephrolithiasis	0.00608	0.0458	CbGeAlD
Dabrafenib—Nephritis interstitial—Hydrochlorothiazide—nephrolithiasis	0.00597	0.0573	CcSEcCtD
Dabrafenib—SLC22A6—nephron tubule—nephrolithiasis	0.0059	0.0445	CbGeAlD
Dabrafenib—RAF1—renal system—nephrolithiasis	0.00552	0.0416	CbGeAlD
Dabrafenib—RAF1—kidney—nephrolithiasis	0.00534	0.0403	CbGeAlD
Dabrafenib—Tubulointerstitial nephritis—Hydrochlorothiazide—nephrolithiasis	0.00526	0.0505	CcSEcCtD
Dabrafenib—RAF1—cortex of kidney—nephrolithiasis	0.0052	0.0392	CbGeAlD
Dabrafenib—SLC22A6—cortex of kidney—nephrolithiasis	0.00505	0.0381	CbGeAlD
Dabrafenib—Gamma-glutamyltransferase increased—Hydrochlorothiazide—nephrolithiasis	0.0049	0.047	CcSEcCtD
Dabrafenib—RAF1—Stimuli-sensing channels—CLCN4—nephrolithiasis	0.00431	0.0162	CbGpPWpGaD
Dabrafenib—RAF1—Stimuli-sensing channels—CLCN5—nephrolithiasis	0.00431	0.0162	CbGpPWpGaD
Dabrafenib—SLCO1B1—renal system—nephrolithiasis	0.00413	0.0312	CbGeAlD
Dabrafenib—SLCO1B1—kidney—nephrolithiasis	0.004	0.0301	CbGeAlD
Dabrafenib—Hyperkalaemia—Hydrochlorothiazide—nephrolithiasis	0.00396	0.038	CcSEcCtD
Dabrafenib—ABCG2—Iron uptake and transport—ATP6V0A4—nephrolithiasis	0.00363	0.0137	CbGpPWpGaD
Dabrafenib—SLC22A8—nephron tubule—nephrolithiasis	0.00353	0.0266	CbGeAlD
Dabrafenib—SLC22A8—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A12—nephrolithiasis	0.00325	0.0122	CbGpPWpGaD
Dabrafenib—LIMK1—Regulation of Actin Cytoskeleton—CHRM3—nephrolithiasis	0.00321	0.0121	CbGpPWpGaD
Dabrafenib—SLC22A8—renal system—nephrolithiasis	0.00321	0.0242	CbGeAlD
Dabrafenib—SLC22A8—kidney—nephrolithiasis	0.0031	0.0234	CbGeAlD
Dabrafenib—SLC22A8—cortex of kidney—nephrolithiasis	0.00302	0.0228	CbGeAlD
Dabrafenib—SLC22A8—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A9—nephrolithiasis	0.00302	0.0114	CbGpPWpGaD
Dabrafenib—Hyponatraemia—Hydrochlorothiazide—nephrolithiasis	0.00294	0.0282	CcSEcCtD
Dabrafenib—Pain in extremity—Hydrochlorothiazide—nephrolithiasis	0.00292	0.0281	CcSEcCtD
Dabrafenib—RAF1—Ion channel transport—CLCN4—nephrolithiasis	0.00281	0.0106	CbGpPWpGaD
Dabrafenib—RAF1—Ion channel transport—CLCN5—nephrolithiasis	0.00281	0.0106	CbGpPWpGaD
Dabrafenib—Blood creatinine increased—Hydrochlorothiazide—nephrolithiasis	0.00274	0.0263	CcSEcCtD
Dabrafenib—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A12—nephrolithiasis	0.00271	0.0102	CbGpPWpGaD
Dabrafenib—Dry skin—Hydrochlorothiazide—nephrolithiasis	0.00268	0.0257	CcSEcCtD
Dabrafenib—Abdominal pain upper—Hydrochlorothiazide—nephrolithiasis	0.00267	0.0256	CcSEcCtD
Dabrafenib—Hypokalaemia—Hydrochlorothiazide—nephrolithiasis	0.00266	0.0255	CcSEcCtD
Dabrafenib—Aspartate aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.00263	0.0253	CcSEcCtD
Dabrafenib—Alanine aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.00258	0.0248	CcSEcCtD
Dabrafenib—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A9—nephrolithiasis	0.00252	0.0095	CbGpPWpGaD
Dabrafenib—ABCG2—nephron tubule—nephrolithiasis	0.00251	0.0189	CbGeAlD
Dabrafenib—Pancreatitis—Hydrochlorothiazide—nephrolithiasis	0.00248	0.0238	CcSEcCtD
Dabrafenib—SLCO1B3—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.0024	0.00907	CbGpPWpGaD
Dabrafenib—Neutropenia—Hydrochlorothiazide—nephrolithiasis	0.00236	0.0227	CcSEcCtD
Dabrafenib—CYP2C8—renal system—nephrolithiasis	0.00235	0.0177	CbGeAlD
Dabrafenib—Hyperglycaemia—Hydrochlorothiazide—nephrolithiasis	0.00228	0.0219	CcSEcCtD
Dabrafenib—CYP2C8—kidney—nephrolithiasis	0.00227	0.0171	CbGeAlD
Dabrafenib—Renal failure—Hydrochlorothiazide—nephrolithiasis	0.00222	0.0213	CcSEcCtD
Dabrafenib—SLCO1B3—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.0022	0.00829	CbGpPWpGaD
Dabrafenib—SLCO1B3—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.0022	0.00829	CbGpPWpGaD
Dabrafenib—Urinary tract infection—Hydrochlorothiazide—nephrolithiasis	0.00219	0.021	CcSEcCtD
Dabrafenib—Haematuria—Hydrochlorothiazide—nephrolithiasis	0.00215	0.0206	CcSEcCtD
Dabrafenib—SLC22A8—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00213	0.00802	CbGpPWpGaD
Dabrafenib—Epistaxis—Hydrochlorothiazide—nephrolithiasis	0.00213	0.0204	CcSEcCtD
Dabrafenib—Oedema peripheral—Hydrochlorothiazide—nephrolithiasis	0.00199	0.0191	CcSEcCtD
Dabrafenib—SLC22A8—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00195	0.00734	CbGpPWpGaD
Dabrafenib—SLC22A8—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00195	0.00734	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by Insulin receptor—ATP6V0A4—nephrolithiasis	0.00188	0.00709	CbGpPWpGaD
Dabrafenib—Arrhythmia—Hydrochlorothiazide—nephrolithiasis	0.00181	0.0173	CcSEcCtD
Dabrafenib—Alopecia—Hydrochlorothiazide—nephrolithiasis	0.00179	0.0172	CcSEcCtD
Dabrafenib—SLC22A6—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00178	0.0067	CbGpPWpGaD
Dabrafenib—Erythema—Hydrochlorothiazide—nephrolithiasis	0.00176	0.0169	CcSEcCtD
Dabrafenib—Back pain—Hydrochlorothiazide—nephrolithiasis	0.0017	0.0163	CcSEcCtD
Dabrafenib—Muscle spasms—Hydrochlorothiazide—nephrolithiasis	0.00169	0.0162	CcSEcCtD
Dabrafenib—SLCO1B3—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00167	0.00629	CbGpPWpGaD
Dabrafenib—SLCO1B3—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00167	0.00629	CbGpPWpGaD
Dabrafenib—Vision blurred—Hydrochlorothiazide—nephrolithiasis	0.00166	0.0159	CcSEcCtD
Dabrafenib—Anaemia—Hydrochlorothiazide—nephrolithiasis	0.00163	0.0156	CcSEcCtD
Dabrafenib—SLC22A6—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00162	0.00613	CbGpPWpGaD
Dabrafenib—SLC22A6—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00162	0.00613	CbGpPWpGaD
Dabrafenib—SLCO1B1—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00162	0.00609	CbGpPWpGaD
Dabrafenib—BRAF—Regulation of Actin Cytoskeleton—CHRM3—nephrolithiasis	0.00161	0.00606	CbGpPWpGaD
Dabrafenib—CYP3A4—renal system—nephrolithiasis	0.00159	0.012	CbGeAlD
Dabrafenib—Leukopenia—Hydrochlorothiazide—nephrolithiasis	0.00158	0.0151	CcSEcCtD
Dabrafenib—SLCO1B3—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.00155	0.00584	CbGpPWpGaD
Dabrafenib—SLCO1B3—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.00155	0.00584	CbGpPWpGaD
Dabrafenib—CYP3A4—kidney—nephrolithiasis	0.00154	0.0116	CbGeAlD
Dabrafenib—Cough—Hydrochlorothiazide—nephrolithiasis	0.00154	0.0147	CcSEcCtD
Dabrafenib—Myalgia—Hydrochlorothiazide—nephrolithiasis	0.0015	0.0144	CcSEcCtD
Dabrafenib—Arthralgia—Hydrochlorothiazide—nephrolithiasis	0.0015	0.0144	CcSEcCtD
Dabrafenib—SLCO1B1—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00148	0.00557	CbGpPWpGaD
Dabrafenib—SLCO1B1—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00148	0.00557	CbGpPWpGaD
Dabrafenib—SLC22A8—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00147	0.00556	CbGpPWpGaD
Dabrafenib—SLC22A8—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00147	0.00556	CbGpPWpGaD
Dabrafenib—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.00147	0.0141	CcSEcCtD
Dabrafenib—Oedema—Hydrochlorothiazide—nephrolithiasis	0.00144	0.0138	CcSEcCtD
Dabrafenib—Thrombocytopenia—Hydrochlorothiazide—nephrolithiasis	0.00141	0.0135	CcSEcCtD
Dabrafenib—Hyperhidrosis—Hydrochlorothiazide—nephrolithiasis	0.00139	0.0133	CcSEcCtD
Dabrafenib—SLCO1B3—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00138	0.00521	CbGpPWpGaD
Dabrafenib—SLC22A8—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.00137	0.00517	CbGpPWpGaD
Dabrafenib—SLC22A8—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.00137	0.00517	CbGpPWpGaD
Dabrafenib—SLCO1B3—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00137	0.00517	CbGpPWpGaD
Dabrafenib—SLCO1B3—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00137	0.00517	CbGpPWpGaD
Dabrafenib—Hypotension—Hydrochlorothiazide—nephrolithiasis	0.00134	0.0129	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.00131	0.0126	CcSEcCtD
Dabrafenib—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.0013	0.0125	CcSEcCtD
Dabrafenib—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.00125	0.012	CcSEcCtD
Dabrafenib—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.00124	0.0119	CcSEcCtD
Dabrafenib—ABCB1—nephron tubule—nephrolithiasis	0.00124	0.00934	CbGeAlD
Dabrafenib—SLC22A6—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00123	0.00464	CbGpPWpGaD
Dabrafenib—SLC22A6—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00123	0.00464	CbGpPWpGaD
Dabrafenib—Constipation—Hydrochlorothiazide—nephrolithiasis	0.00123	0.0118	CcSEcCtD
Dabrafenib—SLC22A8—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00122	0.00461	CbGpPWpGaD
Dabrafenib—SLCO1B3—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00122	0.00461	CbGpPWpGaD
Dabrafenib—SLC22A8—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00121	0.00458	CbGpPWpGaD
Dabrafenib—SLC22A8—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00121	0.00458	CbGpPWpGaD
Dabrafenib—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.00118	0.0113	CcSEcCtD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.00115	0.00433	CbGpPWpGaD
Dabrafenib—SLC22A6—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.00114	0.00432	CbGpPWpGaD
Dabrafenib—SLC22A6—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.00114	0.00432	CbGpPWpGaD
Dabrafenib—Body temperature increased—Hydrochlorothiazide—nephrolithiasis	0.00114	0.0109	CcSEcCtD
Dabrafenib—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.00114	0.0109	CcSEcCtD
Dabrafenib—ABCB1—renal system—nephrolithiasis	0.00113	0.00849	CbGeAlD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—DGKH—nephrolithiasis	0.00112	0.00423	CbGpPWpGaD
Dabrafenib—SLCO1B1—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00112	0.00422	CbGpPWpGaD
Dabrafenib—SLCO1B1—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00112	0.00422	CbGpPWpGaD
Dabrafenib—SLCO1B3—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00112	0.00422	CbGpPWpGaD
Dabrafenib—SLCO1B3—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00112	0.00422	CbGpPWpGaD
Dabrafenib—RAF1—Regulation of Actin Cytoskeleton—CHRM3—nephrolithiasis	0.00111	0.00419	CbGpPWpGaD
Dabrafenib—ABCB1—kidney—nephrolithiasis	0.00109	0.00821	CbGeAlD
Dabrafenib—SLC22A8—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00108	0.00408	CbGpPWpGaD
Dabrafenib—ABCB1—cortex of kidney—nephrolithiasis	0.00106	0.008	CbGeAlD
Dabrafenib—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.00106	0.0102	CcSEcCtD
Dabrafenib—SLCO1B1—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.00104	0.00393	CbGpPWpGaD
Dabrafenib—SLCO1B1—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.00104	0.00393	CbGpPWpGaD
Dabrafenib—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.00103	0.0099	CcSEcCtD
Dabrafenib—SLC22A6—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00102	0.00385	CbGpPWpGaD
Dabrafenib—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.00102	0.00976	CcSEcCtD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00101	0.00382	CbGpPWpGaD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00101	0.00382	CbGpPWpGaD
Dabrafenib—SLC22A8—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.000989	0.00373	CbGpPWpGaD
Dabrafenib—SLC22A8—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.000989	0.00373	CbGpPWpGaD
Dabrafenib—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.000984	0.00944	CcSEcCtD
Dabrafenib—RAF1—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.000978	0.00369	CbGpPWpGaD
Dabrafenib—RAF1—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.000978	0.00369	CbGpPWpGaD
Dabrafenib—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.000951	0.00912	CcSEcCtD
Dabrafenib—SLCO1B1—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.000928	0.0035	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.000921	0.00347	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.000921	0.00347	CbGpPWpGaD
Dabrafenib—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.000914	0.00877	CcSEcCtD
Dabrafenib—Rash—Hydrochlorothiazide—nephrolithiasis	0.000906	0.0087	CcSEcCtD
Dabrafenib—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.000906	0.00869	CcSEcCtD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.000902	0.0034	CbGpPWpGaD
Dabrafenib—Headache—Hydrochlorothiazide—nephrolithiasis	0.000901	0.00864	CcSEcCtD
Dabrafenib—RAF1—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.000872	0.00329	CbGpPWpGaD
Dabrafenib—Nausea—Hydrochlorothiazide—nephrolithiasis	0.000854	0.00819	CcSEcCtD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.000853	0.00322	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.000853	0.00322	CbGpPWpGaD
Dabrafenib—SLCO1B3—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.000847	0.00319	CbGpPWpGaD
Dabrafenib—SLCO1B3—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.000847	0.00319	CbGpPWpGaD
Dabrafenib—CYP2C8—Biological oxidations—SLC26A1—nephrolithiasis	0.000833	0.00314	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.000829	0.00313	CbGpPWpGaD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.000825	0.00311	CbGpPWpGaD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.000825	0.00311	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.000821	0.0031	CbGpPWpGaD
Dabrafenib—RAF1—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.000797	0.00301	CbGpPWpGaD
Dabrafenib—RAF1—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.000797	0.00301	CbGpPWpGaD
Dabrafenib—SLCO1B3—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000787	0.00297	CbGpPWpGaD
Dabrafenib—SLCO1B3—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000787	0.00297	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00076	0.00287	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.000751	0.00283	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.000751	0.00283	CbGpPWpGaD
Dabrafenib—SLC22A8—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.00075	0.00283	CbGpPWpGaD
Dabrafenib—SLC22A8—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.00075	0.00283	CbGpPWpGaD
Dabrafenib—SLCO1B3—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000702	0.00265	CbGpPWpGaD
Dabrafenib—SLCO1B3—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000702	0.00265	CbGpPWpGaD
Dabrafenib—SLC22A8—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000697	0.00263	CbGpPWpGaD
Dabrafenib—SLC22A8—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000697	0.00263	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.000695	0.00262	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.000695	0.00262	CbGpPWpGaD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.000626	0.00236	CbGpPWpGaD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.000626	0.00236	CbGpPWpGaD
Dabrafenib—SLC22A8—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000621	0.00234	CbGpPWpGaD
Dabrafenib—SLC22A8—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000621	0.00234	CbGpPWpGaD
Dabrafenib—BRAF—Focal Adhesion—SPP1—nephrolithiasis	0.000608	0.00229	CbGpPWpGaD
Dabrafenib—RAF1—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.000604	0.00228	CbGpPWpGaD
Dabrafenib—RAF1—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.000604	0.00228	CbGpPWpGaD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000582	0.00219	CbGpPWpGaD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000582	0.00219	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—SLC7A9—nephrolithiasis	0.000578	0.00218	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—DGKH—nephrolithiasis	0.000578	0.00218	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.000569	0.00215	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.000569	0.00215	CbGpPWpGaD
Dabrafenib—RAF1—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000562	0.00212	CbGpPWpGaD
Dabrafenib—RAF1—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000562	0.00212	CbGpPWpGaD
Dabrafenib—SLCO1B3—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000561	0.00212	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000529	0.002	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000529	0.002	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.000527	0.00199	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.000527	0.00199	CbGpPWpGaD
Dabrafenib—RAF1—BDNF signaling pathway—SPP1—nephrolithiasis	0.000525	0.00198	CbGpPWpGaD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000518	0.00195	CbGpPWpGaD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000518	0.00195	CbGpPWpGaD
Dabrafenib—RAF1—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000501	0.00189	CbGpPWpGaD
Dabrafenib—RAF1—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000501	0.00189	CbGpPWpGaD
Dabrafenib—SLC22A8—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000497	0.00187	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—ADCY10—nephrolithiasis	0.000493	0.00186	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—RGS14—nephrolithiasis	0.000491	0.00185	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.00049	0.00185	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.00049	0.00185	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—GRHPR—nephrolithiasis	0.000487	0.00184	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000472	0.00178	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000472	0.00178	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.000461	0.00174	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.000461	0.00174	CbGpPWpGaD
Dabrafenib—BRAF—Disease—SLC26A1—nephrolithiasis	0.000454	0.00171	CbGpPWpGaD
Dabrafenib—CYP3A4—Biological oxidations—SLC26A1—nephrolithiasis	0.000447	0.00169	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000437	0.00165	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000437	0.00165	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—SPP1—nephrolithiasis	0.000435	0.00164	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—AGXT—nephrolithiasis	0.000434	0.00164	CbGpPWpGaD
Dabrafenib—RAF1—Focal Adhesion—SPP1—nephrolithiasis	0.00042	0.00159	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—RGS14—nephrolithiasis	0.00042	0.00158	CbGpPWpGaD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000414	0.00156	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.000411	0.00155	CbGpPWpGaD
Dabrafenib—BRAF—Disease—ATP6V0A4—nephrolithiasis	0.000405	0.00153	CbGpPWpGaD
Dabrafenib—RAF1—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.0004	0.00151	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000377	0.00142	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.000376	0.00142	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.000376	0.00142	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—APRT—nephrolithiasis	0.000369	0.00139	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—SLC26A1—nephrolithiasis	0.000369	0.00139	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000349	0.00132	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ADCY10—nephrolithiasis	0.000341	0.00129	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—DGKH—nephrolithiasis	0.000332	0.00125	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—GRHPR—nephrolithiasis	0.000327	0.00123	CbGpPWpGaD
Dabrafenib—RAF1—Disease—SLC26A1—nephrolithiasis	0.000314	0.00118	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—GRHPR—nephrolithiasis	0.000303	0.00114	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—AGXT—nephrolithiasis	0.000291	0.0011	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—RGS14—nephrolithiasis	0.00029	0.00109	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.000285	0.00107	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.000285	0.00107	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—DGKH—nephrolithiasis	0.000283	0.00107	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000283	0.00107	CbGpPWpGaD
Dabrafenib—RAF1—Disease—ATP6V0A4—nephrolithiasis	0.00028	0.00106	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—AGXT—nephrolithiasis	0.00027	0.00102	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000265	0.000999	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000265	0.000999	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—AQP1—nephrolithiasis	0.000263	0.000991	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—SLC26A1—nephrolithiasis	0.000248	0.000935	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—APRT—nephrolithiasis	0.000248	0.000935	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CHRM3—nephrolithiasis	0.00024	0.000905	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—CHRM3—nephrolithiasis	0.000238	0.000896	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000236	0.00089	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000236	0.00089	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—APRT—nephrolithiasis	0.000229	0.000865	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—SLC26A1—nephrolithiasis	0.000229	0.000865	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—PTH—nephrolithiasis	0.000219	0.000828	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CHRM3—nephrolithiasis	0.000205	0.000773	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000196	0.000739	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—DGKH—nephrolithiasis	0.000196	0.000739	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000189	0.000712	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GRHPR—nephrolithiasis	0.000188	0.000709	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PTH—nephrolithiasis	0.000187	0.000707	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—AQP1—nephrolithiasis	0.000177	0.000666	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—AGXT—nephrolithiasis	0.000167	0.000632	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GRHPR—nephrolithiasis	0.000164	0.000617	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—AQP1—nephrolithiasis	0.000163	0.000617	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CHRM3—nephrolithiasis	0.00016	0.000602	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CHRM3—nephrolithiasis	0.000148	0.000558	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—AGXT—nephrolithiasis	0.000146	0.00055	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—SLC26A1—nephrolithiasis	0.000142	0.000537	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—APRT—nephrolithiasis	0.000142	0.000537	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CHRM3—nephrolithiasis	0.000142	0.000535	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PTH—nephrolithiasis	0.00013	0.000489	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—SLC26A1—nephrolithiasis	0.000124	0.000468	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—APRT—nephrolithiasis	0.000124	0.000468	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—AQP1—nephrolithiasis	0.000101	0.000383	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GRHPR—nephrolithiasis	0.000101	0.00038	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—SPP1—nephrolithiasis	9.41e-05	0.000355	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CHRM3—nephrolithiasis	9.18e-05	0.000346	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—AGXT—nephrolithiasis	8.99e-05	0.000339	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—AQP1—nephrolithiasis	8.84e-05	0.000333	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CHRM3—nephrolithiasis	7.99e-05	0.000301	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SLC26A1—nephrolithiasis	7.64e-05	0.000288	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—APRT—nephrolithiasis	7.64e-05	0.000288	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SPP1—nephrolithiasis	6.51e-05	0.000245	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—AQP1—nephrolithiasis	5.45e-05	0.000205	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CHRM3—nephrolithiasis	4.93e-05	0.000186	CbGpPWpGaD
